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Abstract
Patients were identified from a population-based prospective study of 4990
individuals with symptoms associated with colorectal cancer (CRC). A total of
244 CRC tissue samples were available for immunohistochemical staining of
uPAR, semiquantitatively scored at the invasive front, and in the tumor core on
cancer cells, macrophages, and myofibroblasts. In addition, the levels of the
intact and cleaved uPAR-forms in blood from the same patients are evaluated
in this study. In a univariate analysis, the number of uPAR-positive versus
uPAR-negative macrophages (HR = 2.26, [95% CI: 1.39–3.66, P = 0.0009]) and
cancer cells (HR=1.49, [95% CI: 1.01–2.20, P = 0.047]) located in the tumor
core were significantly associated to overall survival. In a multivariate analysis,
uPAR-positive versus uPAR-negative macrophages located in the tumor core
showed the best separation of patients with positive score associated to poor
prognosis (HR = 1.84 [95% CI: 1.12–3.04, P = 0.017]). In a multivariate analy-
sis including clinical covariates and soluble uPAR(I), the latter was significantly
associated to overall survival (HR = 2.68 [95% CI: 1.90–3.79, P < 0.0001]) and
uPAR-positive macrophages in the tumor core remained significantly associated
to overall survival (HR = 1.81 [95% CI: 1.08–3.01, P = 0.023]). Membrane-
bound uPAR showed additive effects with the circulating uPAR(I) and stage,
giving a hazard ratio of 12 between low and high scores. Thus, combining
stage, uPAR(I) in blood and uPAR on macrophages in the tumor core increase
the prognostic precision more than tenfold, as compared to stage alone.
Introduction
Colorectal adenocarcinomas constitute a complex
environment of stromal elements apart from a rather
heterogeneous tumor cell population (for review, see [1]).
This implies that in some cases the presumably normal
“appearing” accessory cells may outnumber the malignant
cells. Although immune reactions against the malignant
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cells are common, the immune cells—and mainly macro-
phages—may become polarized to collaborate with the
neoplastic cell population and thus contribute to the malig-
nant behavior [2]. In addition, the formation of local blood
vessels as well as connective tissue is necessary for tumor
invasion, progression, and dissemination [1].
Recently, we have examined the importance of the plas-
minogen-activating system in adenocarcinomas in other
locations of the gastrointestinal tract (GI-tract). Activa-
tion of plasminogen to plasmin in the tumor microenvi-
ronment leads to a cascade of proteolytic activities in
addition to malignant cell migration and angiogenesis,
thus enhancing invasion and dissemination [3]. The uro-
kinase-type plasminogen receptor (uPAR) is of particular
importance for this process, as receptor binding is a pre-
requisite for pericellular plasmin formation, which is
required for tissue remodeling during cancer invasion [4].
Increased expression of uPAR is most likely associated to
increased invasive capability in different malignant
tumors. The expression and localization of uPAR in
tumor tissue may thus be of clinical importance [5].
In gastric adenocarcinomas, we found that uPAR-
expression on a high percentage of the malignant cells at
the invasion front of the tumor was associated with poor
prognosis [6]. In adenocarcinomas of the lower eso-
phagus, a cancer type with a dismal prognosis a high pro-
portion of uPAR-positive cells was found among cancer
cells, macrophages, and myofibroblasts. uPAR-upregula-
tion was even seen in nerve bundles close to the tumor.
This indicates that there is a strong local stimulus for
uPAR-expression in the microenvironment of the invasive
area. In this type of cancer, the number of uPAR-positive
malignant cells in tumor core and the number of uPAR-
positive macrophages at the invasive zone were associated
to a worse prognosis. In the invasion zone, the cancer
tissue showed deep penetration into the esophageal wall
and surrounding tissue [7].
In colorectal cancer (CRC), uPAR has been localized to
the invasive front and expressed mainly by macrophages
but also expressed by some myofibroblasts and by a few
cancer cells, the so-called budding cancer cells [8, 9]. The
prognostic significance of uPAR-forms in tumor-tissue
from CRC patients has previously been determined by
immunoassay quantification in tumor-tissue extracts [10].
The protein consists of three domains and is attached to
the cell membrane via a glycolipid anchor. On the cell
surface, intact uPAR [uPAR(I–III)] is cleaved, liberating
the amino-terminal domain I [uPAR(I)], and leaving the
cleaved uPAR(II-III) on the cell surface. The two cell sur-
face-bound forms can be shed and thus three soluble
forms of uPAR can be identified in the blood [11]. The
functions, if any, of soluble uPAR(I–III) and uPAR(I) are
not clarified, whereas soluble-cleaved uPAR(II–III) have
been demonstrated to be involved in chemotaxis [11].
The combined amount of the soluble uPAR-forms in
plasma from CRC patients is a strong prognostic marker
with high levels correlating to poor prognosis [12], and
interestingly the liberated uPAR(I) and the uPAR
(I–III) + uPAR(II–III) are independent prognostic mar-
kers [13]. The levels of the cleaved uPAR-forms could
reflect pericellular proteolytic activity from the tumor,
and thus be a measure of invasive activity.
We here present evidence that although uPAR is pre-
sent on both cancer cells and myofibroblasts, expression
on macrophages seems to be a substantial prognostic fac-
tor. Furthermore, when the number of uPAR-positive
macrophages in tumor core was combined with the
plasma level of uPAR(I) and stage, this separated the
patients into distinct groups with several fold differences
in overall survival.
Materials and Methods
Patients
From November 2003 through December 2005, patients
were included in a multicenter cross-sectional study
conducted at six Danish hospitals. Eligible for inclusion
were patients (aged 18+ years) undergoing endoscopic
examination following symptoms related to CRC and
patients attending surveillance programs due to hereditary
CRC [14]. A total of 303 patients were diagnosed with
CRC. Routine-fixated paraffin-embedded tumor-tissue
blocks from 281 of these were available, 22 patients were
not resectable. There were, however, evaluable specimens
from only 244 patients, which were included in the present
study. Disease stage was based on the tumor, node, metas-
tasis-stage (TNM-stage) (International Union Against
Cancer [UICC] [http://www.uicc.org/resources/]). Citrate
plasma samples were collected from the CRC patients
before large bowel endoscopy as described previously [13].
The clinical data for these patients are presented in
Table 1. Use of the patient material was approved by The
Regional Ethical Committee of Copenhagen and Frederi-
ksberg (KF 01-080/03) and the Danish Data Protection
Agency (2003-41-3312) approved the protocol and the
study was carried out according to the Helsinki Declara-
tion II.
Antibodies
Rabbit polyclonal antibody (pAb) and a mouse monoclo-
nal antibody (mAb) (clones R2, IgG1) against uPAR have
been described previously [15, 16]. MAbs against pan-
cytokeratin (pan-CK) (clone AE1/AE3) and CK20 (clone
Ks20.8) for detection of cancer cells, CD68 for detection
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of macrophages (clone PG-MI), and a-smooth-muscle-
actin (a-SMA) for detection of myofibroblasts (clone
1A4)—as well as EnVision horseradish peroxidase Mouse
(K4001), EnVision horseradish peroxidase Rabbit (K4003)
secondary antibodies, and an EnVisionTM G│2 Double
Staining Kit (K5361) were purchased from Dako
(Glostrup, Denmark).
Immunoperoxidase staining
Three-micrometer paraffin sections from each of the
blocks were deparaffinized with xylene and hydrated
through ethanol/water dilutions. Sections, which were
stained with uPAR-antibodies (pAb and R2), were pre-
treated with Proteinase K (5 lg/lL) in a Proteinase
K-buffer (50 mmol/L Tris-HCl, 50 mmol/L EDTA, pH
8.0) at 37°C for 15 min, and sections stained with the
a-SMA antibody were pretreated at 98°C in TEG-buffer
(10 mmol/L Tris-HCl, 0.5 mmol/L EGTA, pH 9.0) for
10 min using a T/T Micromed microwave processor
(Milestone, Sorisol, Italy). Immunohistochemical stainings
were performed using a LabVision Autostainer 360 (Lab-
Vision, Freemont, CA). The autostainer was programmed
with two drop zones per section; each with 100 lL.
Endogenous peroxidase was blocked by incubation in 1%
H2O2 for 15 min and thereafter rinsed in Tris-buffered
saline (TBS-T, 50 mmol/L Tris-HCl, 150 mmol/L NaCl,
0.5% Triton X-100, pH 7.6). The primary antibodies were
diluted in Antibody Diluent with Background-Reducing
Components (S3022, Dako) at the following concentra-
tions: uPAR pAb (2.8 lg/mL), uPAR clone R2 (0.86 lg/
mL), a-SMA antibody (0.35 lg/mL), and added to the
section. After 30 min incubation the primary antibodies
were detected with EnVision Rabbit or Mouse reagents for
30 min. The sections were then developed with NovaRed
(Vector Laboratories, Burlingame, CA) for 15 min. Each
incubation step was followed by washes in TBS-T. Finally,
the sections were counterstained using ½9 Mayer’s hema-
toxylin for 1 min, and thereafter removed from the auto-
stainer and dehydrated in ethanol solutions and mounted
with pertex using a CoverSlipper from Dako.
Double immunohistochemistry
Paraffin sections of 3 lm were double stained using anti-
bodies against CD68 and CK-mix (CK-pan + CK20). Sta-
inings were performed with the EnVisionTM G│2 Double
Staining Kit using the protocol provided by the manufac-
turer. Antigen retrieval was performed with Proteinase K
(5 lg/lL) in a Proteinase K-buffer at 37°C for 15 min.
After pretreatment, the slides were mounted on Shandon
racks with immunostaining cover plates (Thermo Shan-
don, Pittsburgh, PA). Subsequently, the endogenous per-
oxidase activity was blocked by incubation with H2O2
provided in the kit for 15 min. The antibody against
CD68 (0.30 lg/mL) was diluted in Antibody Diluent with
Background-Reducing Components and added to the slide
and incubated for 2 h at room temperature. The detection
was done with a secondary antibody and then developed
with 3.3-diaminobenzidine (DAB). Thereafter, the second
primary antibody (CK-pan [0.54 lg/lL], CK20 [0.68 lg/
lL]) was added to the slides and incubated overnight at
4°C. The second primary antibody was detected with a
secondary antibody, which then was developed with Per-
manent Red. The sections were counterstained using
150 lL Mayer’s hematoxylin for 30 sec and were finally
dehydrated in an oven at 60°C for 1 h before coverslips
were mounted using a Dako CoverSlipper.
Scoring
The sections stained for uPAR using the anti-uPAR pAb
were coded and evaluated blindly by two experienced
pathologists (O. D. L. and J. P. H.). uPAR is expressed by
circulating neutrophils. These served as internal positive
control for the uPAR-stainings [17]. Sections with uPAR-
negative neutrophils were restained.
uPAR-immunoreactivity was scored separately in can-
cer cells, macrophages, and myofibroblasts, as described
Table 1. Patients’ characteristics.
N (%) Association1
Age 70.5 (32.7–91.7)2 0.46, 0.07, 0.303
0.42, 0.11, 0.48
Gender M 148 (61) 0.10, 0.86, 0.944
F 96 (39) 0.74, 0.33, 0.66
Localization Right-sided
colon cancer
56 (23)
Left-sided
colon cancer
95 (39) 0.039, 0.003, 0.0114
Rectal cancer 93 (38) 0.12, 0.39, 0.09
Stage I 41 (17)
II 82 (34) 0.20, 0.67, 0.804
III 66 (27) 0.81, 0.45, 0.51
IV 45 (18)
Not staged 10 (4)
Chemotherapy No 183 (75) 0.008, 0.09, 0.0014
Yes 61 (25) 0.005, 0.64, 0.049
1P-values for the association between the clinical variable and uPAR-
scores for the cancer cells/core, macrophages/core, myofibroblasts/
core, cancer cells/invasive front, macrophages/invasive front and myo-
fibroblasts/invasive front, respectively.
2Median age and range.
3P-values for Spearman rank correlations.
4P-values for the Wilcoxon rank-sum test.
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previously [6, 7]. These cell types were identified in
neighboring sections by immunohistochemical stainings
for CKs (cancer cells) and CD68 (macrophages), and
a-SMA (myofibroblasts). The counting of uPAR-positive
cells was performed independently in two locations of the
tumors, the invasion zone (defined up to 0.5 mm broad
in the tumor periphery), and in the tumor core (every-
thing else but areas of necrosis, see also [6, 7]). The per-
centages of uPAR-positive cells were grouped into the
following categories: 0, no uPAR-positive cells detected; 1,
less than 1% positively stained cells; 2, between 1% and
5% positive cells; 3, between 5% and 10% positive cells
and 4, more than 10% positively stained cells.
In addition to the uPAR-scoring, the size of the CD68-
positive macrophages was evaluated by two independent
observers (O. D. L. and M. I.). Macrophages smaller than
the diameter of two leukocytes were considered small,
whereas macrophages exceeding the diameter of two
leukocytes were considered large.
Measurements of uPAR-forms
The levels of the different soluble uPAR-forms in all the
patient citrate plasma samples were measured using time-
resolved fluorescence immunoassays [13].
Statistics
The uPAR-scores were dichotomized as negative
(score = 0) and positive (score > 0). Comparisons
between the uPAR-scores, the actual score as well as the
dichotomized scores were compared to the clinical covari-
ates using rank statistics. Interobserver agreement was
evaluated using the Spearman rank correlation, tests for
symmetry, and weighted Kappa statistics. Interobserver
agreement for CD68 measurements was assessed by Kappa
statistics with 95% confidence limits. The measured
uPAR-forms [uPAR(I–III), uPAR(I–III)+uPAR(II–III) and
uPAR(I)] were all analyzed on the log scale (base 2)
(resulting hazard ratio [HR] in twofold difference in the
marker levels). Survival probabilities for time to death of
all causes have been estimated employing the Kaplan–
Meier method. The association between the clinical cova-
riates and the uPAR-scores has been done using the Cox
proportional hazards model for univariate as well as mul-
tivariable analysis. Multivariable analysis of the uPAR-
scores included only those covariates that were statistically
significant in the univariate setting. Results are presented
by the HR with 95% confidence interval (CI) and a ge-
neralized concordance-index (C-index) [18]. The assump-
tions of the regression models were assessed using
martingale and Sch€onfeld residuals and 10-fold internal
cross-validation. P-values less than 5% were considered
significant. Statistical calculations have been done using
SAS (v9.2, SAS Institute, Cary, NC) and R (R Core Team
[2013]. R: A language and environment for statistical
computing. R statistical Computing, Vienna, Austria. URL.
http://www.R-project.org/). The results of this project are
reported in accordance with the REMARK guidelines [19].
Results
uPAR-immunohistochemistry
Sections from each of the 244 biopsies of CRC were pro-
cessed for immunohistochemistry using the pAb and
mAb against uPAR. Identical stainings were seen for the
two uPAR-antibodies, and sections stained with pAb
against uPAR were used for further analysis. Immunohis-
tochemical stainings for specific cell markers, such as CKs
for cancer cells and CD68 for macrophages (double stain-
ing) and a-SMA for myofibroblasts were in addition
performed on adjacent sections (Fig. 1).
When evaluating the CK-stained sections, we found
that no tumor invasive front was present in specimens
from two of the patients. These samples were censored,
therefore, the invasive front have been analyzed in 242
specimens and tumor core in all 244 evaluable specimens.
The pAb against uPAR has been validated in earlier stu-
dies [6, 7, 9].
uPAR-immunoreactivity was seen in primarily tumor-
associated macrophages (TAMs) at the invasive front in
183 of the 242 biopsies (Fig. 1A and B). Macrophages
positive for uPAR were also observed in the tumor core
in 176 of the cases and also seen in macrophages in lumi-
nal parts of the cancer glands and in areas with necrosis
(Fig. 1C and D). uPAR-positivity was also seen in bud-
ding cancer cells located at the invasive front in 195 of
the cases as well as in the tumor core in 150 of the cases
(Fig. 1A and B). Myofibroblasts located at the invasive
front were uPAR-positive in 208 of the cases and myofi-
broblasts located at the tumor core were positive in 134
of the cases (Fig. 1A and data not shown). uPAR-immu-
noreactivity was also observed in the endothelial cells
located in vascular structures of the submucosa and in
distal and proximal nerve bundles located in the submu-
cosa. In 21 of the cases, uPAR-immunoreactivity was only
seen in infiltrating neutrophils scattered throughout the
tissue. The finding described above confirms previous
localization studies in human CRC [8, 9].
Scoring of uPAR-positive cells
In order to validate the uPAR-scoring of the specimens
by (O. D. L.) the other trained pathologist (J.P.H.) scored
specimens from 71 patients for uPAR-positivity on each
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of the three cell types at the invasive front and in the
tumor core. Statistical examination of the agreement
between the different uPAR-scores is shown in Table 2.
These results suggest a moderate agreement between the
observers, although there was a slight systematic
difference. Statistical analysis of the second observer’s
scores demonstrated similar trends as the first observer
(data not shown). The first observer’s (O. D. L.) uPAR-
scorings were then used for further analysis.
The number of uPAR-positive cells of any of the three
types was higher at the invasive front than in the tumor
core, and in both locations, the scores for the macrophages
were the highest. Median scores were 1 for cancer cells/
tumor core, 2 for macrophages/tumor core, 1 for myofibro-
blasts/tumor core, 3 cancer cells/invasive front, 4 for mac-
rophages/invasive front, and 3 for myofibroblasts/invasive
front (Table 2). For statistical analysis, however, the uPAR-
scores were dichotomized as negative (score = 0) and posi-
tive (score > 0). The clinical covariates and P-values for
their association with the uPAR-scores are presented in
Table 1. Significant associations between the uPAR-scores
for tumor core are seen for cancer location with colon
cancer patients having higher scores than those with rectal
cancer. The rank correlations between the uPAR-scores are
considered moderate (0.28–0.64).
In an univariate analysis, the number of uPAR-positive
versus uPAR-negative macrophages (HR = 2.26 [95% CI:
1.39–3.66, P = 0.0009]) and cancer cells (HR = 1.49
A B
C D
Figure 1. Immunohistochemical identification of macrophages, cancer cells and uPAR-expressing cells. Adjacent tissue sections of CRC were
processed for either uPAR-immunohistochemistry using a pAb against uPAR (A and C), or double immunohistochemistry for CKs and CD68 using
the Envision G|2 Double System kit from Dako (B and D). The uPAR-stainings are visualized with NovaRed, the CK-stainings with Permanent Red
and the CD68-stainings with DAB. Intense uPAR-immunoreactivity is seen at the invasive front primarily in cells identified as macrophages (black
arrows in A and B) but also in some budding cancer cells (blue arrows in A and B), and some myofibroblasts (green arrows in A). uPAR-
immunoreactivity is also seen in neutrophils scattered throughout the tissue (red arrows in A). Strong uPAR-immunoreactivity is often seen in
large macrophages within the tumor core (C and D). Bar in A: ~50 lm. DAB, diaminobenzidine; uPAR, urokinase-type plasminogen activator
receptor; CRC, colorectal cancer.
Table 2. Interobserver agreement.
Spearman rank
correlation
Test for
symmetry
(P-value)
Weighted
Kappa
95% CI
for Kappa
Cancer cells/
tumor core
0.61 0.026 0.41 0.27–0.54
Macrophages/
tumor core
0.58 0.25 0.38 0.24–0.53
Myofibroblasts/
tumor core
0.53 0.006 0.37 0.23–0.51
Cancer cells/
invasive front
0.69 0.0007 0.51 0.38–0.64
Macrophages/
invasive front
0.57 0.09 0.41 0.25–0.57
Myofibroblasts/
invasive front
0.66 0.08 0.50 0.36–0.63
The Spearman rank correlations between the semiquantitative scores
of uPAR assessed by two observers are shown in the first column, the
second column gives P-values for tests of symmetry for these scores
and the third measure is the weighted Kappa statistic with 95% CI.
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[95% CI: 1.01–2.20, P = 0.047]) located in the tumor
core were significantly associated to overall survival, while
other parameters were not significant (Table 3). Kaplan–
Meier estimates of survival probabilities for these are
shown in Figure 2.
In a multivariate analysis, uPAR-positive versus uPAR-
negative macrophages located in the tumor core showed
the best separation of patients with good and bad
prognosis (HR = 1.84 [95% CI: 1.12–3.04, P = 0.017]).
There was no association or interaction between number
of uPAR-positive cells and stage, cancer location, gender,
and age (Table 4).
Scoring of CD68-positive macrophages
Because the highest uPAR-scores were obtained for macro-
phages in both tumor core and at the invasive front, we
scored macrophages (CD68-positive cells) (Fig. 1B and D)
according to size on specimens from 201 patients. The
results were assessed by two observers (O. D. L. and M. I.).
In the tumor core, observer 1 (O. D. L.) found 35% and
observer 2 (MI) found 31% of the patients with large
macrophages. At the invasive front, observer 1 found large
macrophages in 75% of the patients and observer 2 in 68%.
There was no association between the ratio of large to small
macrophages and survival [for the tumor core HR = 1.38
(95% CI: 0.94–2.03, P = 0.10) and HR = 0.84 (95% CI:
0.52–1.35, P = 0.47) for the invasive front]. The results
showed, however, that a higher proportion of large macro-
phages were uPAR-positive (data not shown). The observa-
tion of large macrophages in some of the biopsies may
reflect a higher phagocytotic activity, which may therefore
be so-called M2-polarized macrophages [20].
Table 3. Association of uPAR-scores to overall survival. Univariate
analysis.
Positive
(%)
Hazard
ratio 95% CI P-value
Tumor
core
Cancer cells 61 1.49 1.01–2.20 0.047
Macrophages 72 2.26 1.39–3.66 0.0009
Myofibroblasts 55 1.27 0.88–1.84 0.21
Invasive
front
Cancer cells 81 0.94 0.60–1.48 0.80
Macrophages 72 0.77 0.52–1.15 0.21
Myofibroblasts 86 1.54 0.85–2.81 0.16
The proportion of positive scores for each cell type for the tumor core
and invasive front are shown with the results of the univariate analysis
of overall survival presented by the hazard ratio with 95% CI compa-
ring positive to negative scores and the P-value. uPAR, urokinase-type
plasminogen activator receptor.
A
B
Figure 2. Kaplan–Meier estimates of survival probabilities. (A) uPAR on cancer cells in the tumor core stratified by uPAR-score 0 versus uPAR-
score 1–4. (B) Macrophages in the tumor core stratified by uPAR-score 0 versus uPAR-score 1–4. The numbers of patients at risk at 0, 24, and
48 months are shown below the abscissa for each stratum. In addition, the number of deaths in each group is shown to the left. The P-values
shown are for the log rank statistic. uPAR, urokinase-type plasminogen activator receptor.
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Soluble uPAR measurements
The rank correlation between uPAR(I) and uPAR-immu-
nohistochemistry range from 0.03 to 0.10, uPAR(III)
and uPAR-immunohistochemistry range from 0.06 to
0.12, and uPAR(I–III) + uPAR(II–III) range from 0.06 to
0.16. The prognostic significance of the intact and cleaved
soluble uPAR-forms has previously been determined in
citrate plasma from 298 patients, including the 244
patients in the present study [13]. Including uPAR(I–
III) + uPAR(II–III) in the multivariate model showed
that the soluble form was significantly (HR = 2.46 95%
[CI: 1.81 to 3.45, P < 0.0001]) and uPAR-positive macro-
phages/tumor core remained significantly related to over-
all survival (P < 0.0001). Similarly for uPAR(I), the
results were HR = 2.68 (95% CI: 1.90–3.79, P < 0.0001)
and uPAR-positive macrophages/tumor core remained
significant (P = 0.023). These results demonstrate that
the uPAR-positive macrophages in tumor-tissue and the
soluble uPAR-forms in plasma are independent variables.
The uPAR-expressing macrophages in tumor core and
uPAR(I) are additive in the model with a nonsignificant
interaction term (P = 0.90) and thus there is no evidence
of a synergistic effect. No interaction between uPAR-
expressing macrophages/tumor core and stage was
demonstrated (P = 0.76) suggesting that this is additive
to that of stage.
Using the multivariate analysis to stratify the patients
according to stage, uPAR-positive macrophages in tumor
core and level of uPAR(I) in plasma resulted in a remark-
able separation, the HRs for a patient with uPAR-posi-
tive/negative and uPAR(I) equal to the first and third
quartile for stages II and III are shown (Fig. 3). A patient
with stage III and uPAR-positive macrophages/tumor core
and high uPAR(I) level had a 12-fold (95% CI: 9.3–15.4)
higher hazard than a patient in stage II with negative
macrophage/tumor core score and a low uPAR(I) level.
The C-indices for the multivariate model were 0.76 in
stage I, 0.79 in stage II, 0.77 in stage III, and 0.80 in stage
IV suggesting that the model predicts patient outcome
with reasonable accuracy. There was no significant inter-
action for overall survival between adjuvant chemotherapy
and uPAR-positive/negative and uPAR(I) (P = 0.23 and
P = 0.73, respectively), showing the association of the two
Table 4. Multivariable analysis.
Covariates
uPAR-scoring included
uPAR-scoring and plasma uPAR-forms
included
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age pr. 10 years 1.29 1.08–1.54 0.005 1.17 0.98–1.40 0.09
Gender M 1.51 1.00–2.27 0.048 1.65 1.10–2.47 0.015
F 1 1 1 1
Localization Right colon cancer 2.13 1.24–3.68 0.020 1.55 0.86–2.78 0.32
Left colon cancer 1.29 0.80–2.08 1.15 0.70–1.90
Rectal cancer 1 1 1 1
Stage I 1 1 <0.0001 1 1 <0.0001
II 1.17 0.56–2.44 1.04 0.50–2.17
III 2.71 1.30–5.66 3.12 1.48–6.58
IV 10.28 4.68–23 8.59 3.88–19
Chemotherapy No 1 1 0.067 1 1 0.27
Yes 0.61 0.36–1.03 0.74 0.43–1.27
Cancer cells tumor core Neg 0.261
Pos
Macrophages tumor core Neg 1 1 0.017 1 1 0.023
Pos 1.84 1.12–3.04 1.81 1.08–3.01
uPAR(I–III) + uPAR(II–III) Log2 0.14
2
uPAR(I) Log2 2.68 1.90–3.79 <0.0001
1P-value to include in the model. Excluding uPAR-positive macrophages in the tumor core from the analysis results in uPAR-positive cancer cells in
the tumor core being included with HR = 1.55 (95% CI: 1.03–2.34), P = 0.036.
2P-value to include in the model. Excluding uPAR(I) from the model results in uPAR(I–III)+uPAR(II–III) being included, HR = 2.46 (95% CI: 1.81 to
3.35), P < 0.0001.
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uPAR-markers to overall survival was independent of
adjuvant chemotherapy (stage I–III).
Discussion
In the present work, we show that a high uPAR-score on
macrophages in the tumor core is an indicator of poor
prognosis. Although significant, uPAR-positive cancer
cells had less prognostic impact (Fig. 2A and B). These
circulating uPAR-forms are also strong prognostic
markers and independent of the glycolipid-anchored
uPAR on macrophages in tumor core (Table 4).
There are several factors that can explain why different
molecular forms of uPAR are independent prognostic
markers. For the cell surface-bound uPAR-forms, we have
restricted the analysis of association with prognosis to
specific cell types and specific locations in the heteroge-
neous primary tumor. In contrast, blood is homogeneous
and contains soluble uPAR-forms most likely derived
from all uPAR-expressing cells in the body by at least two
different mechanisms. uPAR(I) is released into the blood
by proteolytic cleavage of intact uPAR on the cell surface.
The two glycolipid-anchored uPAR-forms can be shed
from the cell surface, thereby entering the blood [11].
In CRC uPAR is mainly expressed by macrophages at the
invasive front [9]. We found, however, only a significant
correlation with prognosis of uPAR-expressing macro-
phages in the tumor core. As the invasion zone is rather
narrow, in our definition less than 0.5 mm, while tumor
core represents the bulk of a large, solid tumor, lack of
significance for the invasion zone is not surprising.
This supports that the so-called TAMs can exert impor-
tant functions in the microenvironment of CRC. Our
hypothesis is therefore that polarization of an abundance
of so-called M1-macrophages peripherally may lead to
antitumoral capability, while the bulk of the intratumoral
macrophages become tumor-promoting M2-macrophages.
These processes are known to be governed by cytokines.
TAMs may therefore have fundamental modulating effects
on the neoplastic cell population, including tumor cell
growth, cell migration, and invasion as well as angiogene-
sis [20, 21]. It follows that a high density of such macro-
phages is associated with a poor prognosis in most
malignant tumors [22].
The pattern of uPAR-expression on the cell surface in
colorectal carcinomas is similar to the expression and
correlation with poor survival in esophageal and gastric
adenocarcinomas [6, 7]. There are, however, important dif-
ferences. In the esophageal cancers, poor prognosis is
related to a high uPAR-score on cancer cells in the tumor
core and a high percentage of uPAR-positive macrophages
at the narrow invasion zone in the periphery of the tumor.
In contrast, in gastric cancer the prognosis is worst, when a
high number of cancer cells at the invasion zone are uPAR-
positive. At the same time, overall survival in gastric and
particularly in esophageal adenocarcinomas is considerably
poorer than in CRC. Expression of uPAR on myofibro-
blasts was not associated to survival in any of these three
cancer types of the GI-tract (Table 3) [6, 7]. Thus, an
explanation for this survival difference may be that in CRC,
the invasion zone is dominated by tumor-inhibitory mac-
rophages [23]. Therefore, elucidation of such biological
differences between malignant neoplasms of the same his-
tological type in various locations of the same organ system
—here the GI-tract—may be of clinical value.
It is worth noting that the association of uPAR-
expressing cancer cells and macrophages to survival was
independent of stage. This indicates that plasminogen
activation with all the successive effects is an inherent
property of the tumor from the beginning of malignant
Figure 3. Forest plot showing estimated HRs with 95% CI for stage II or III,  uPAR-positive macrophages in tumor core and level of uPAR(I) in
plasma at the first (23.9 pmol/L) and third quartiles (41.8 pmol/L). uPAR, urokinase-type plasminogen activator receptor; HR, hazard ratio; MØ,
macrophages; TC, tumor core.
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growth until the end stage. It is already shown that in
esophageal carcinomas, premalignant lesions were uPAR-
negative until early stromal invasion occurred [7]. There-
fore, high expression of this receptor may be important
for early cancer dissemination.
Recently, a large study on the presence of disseminated
tumor cells in the bone marrow at operation for CRC has
been reported [24]. Survival was found to be gradually
lower over an observation time of 6 years, when carci-
noma cells had been retrieved in the bone marrow. This
indicates that an important part of the tumor dissemina-
tion occurs at an early clinical stage. This could be partly
explained by tumor kinase activity and early angiogenic
signaling [25]. It could therefore be speculated that plas-
minogen activation promoting early infiltration, including
vascular invasion, may be one of the key factors enabling
micrometastasis and further angiogenic signaling.
We conclude that in CRC a high uPAR-score on
tumor-associated macrophages and to a lesser extent on
the cancer cells in the tumor core is associated with poor
survival. Unlike adenocarcinomas in the upper GI-tract,
that is, esophagus and stomach, this outcome is not
related to the peripheral invasion zone. By combining
three independent variables from our multivariate model,
the outcome of the CRC could be discriminated with a
factor of more than 10 (Fig. 3). Thus, the combination of
stage, macrophage uPAR in tumor core and preoperative
plasma uPAR(I) may be a promising predictor of overall
survival after resection of the primary tumor.
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